NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 20 04:00PM ET
20.08
Dollar change
-0.69
Percentage change
-3.32
%
Index- P/E- EPS (ttm)-2.58 Insider Own4.99% Shs Outstand98.25M Perf Week-46.18%
Market Cap1.97B Forward P/E7.31 EPS next Y2.75 Insider Trans-0.05% Shs Float93.37M Perf Month-49.79%
Enterprise Value2.79B PEG- EPS next Q0.68 Inst Own90.15% Short Float9.92% Perf Quarter-72.66%
Income-248.39M P/S0.88 EPS this Y-272.66% Inst Trans-0.96% Short Ratio1.99 Perf Half Y-84.16%
Sales2.23B P/B1.73 EPS next Y172.92% ROA-7.43% Short Interest9.26M Perf YTD-83.49%
Book/sh11.63 P/C3.77 EPS next 5Y19.75% ROE-23.61% 52W Range18.30 - 173.25 Perf Year-82.81%
Cash/sh5.32 P/FCF- EPS past 3/5Y- - ROIC-9.99% 52W High-88.41% Perf 3Y-70.03%
Dividend Est.- EV/EBITDA- Sales past 3/5Y39.42% 37.94% Gross Margin80.07% 52W Low9.73% Perf 5Y-87.36%
Dividend TTM- EV/Sales1.25 EPS Y/Y TTM-1881.09% Oper. Margin-5.25% Volatility26.82% 12.60% Perf 10Y-28.59%
Dividend Ex-Date- Quick Ratio2.46 Sales Y/Y TTM59.15% Profit Margin-11.12% RSI (14)20.47 Recom2.07
Dividend Gr. 3/5Y- - Current Ratio4.02 EPS Q/Q-1361.33% SMA20-42.65% Beta0.60 Target Price54.00
Payout0.00% Debt/Eq1.18 Sales Q/Q80.15% SMA50-54.35% Rel Volume2.71 Prev Close20.77
Employees1372 LT Debt/Eq1.18 EarningsMay 06 AMC SMA200-79.13% Avg Volume4.65M Price20.08
IPOJun 04, 1997 Option/ShortYes / Yes EPS/Sales Surpr.-43.44% 8.35% Trades Volume12,622,926 Change-3.32%
Date Action Analyst Rating Change Price Target Change
Jun-20-25Downgrade William Blair Outperform → Mkt Perform
Jun-18-25Downgrade TD Cowen Buy → Hold $24
Jun-17-25Initiated Wolfe Research Peer Perform
Jun-16-25Downgrade Piper Sandler Overweight → Neutral $36
Jun-16-25Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-25Downgrade H.C. Wainwright Neutral → Sell $10
Jun-16-25Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-16-25Downgrade BofA Securities Buy → Neutral
Jun-16-25Downgrade BMO Capital Markets Outperform → Market Perform $70
Jun-06-25Upgrade Scotiabank Sector Perform → Sector Outperform
Jun-20-25 04:08PM
11:56AM
11:56AM
11:27AM
Jun-19-25 09:45AM
03:00AM Loading…
03:00AM
Jun-18-25 11:39AM
09:51AM
Jun-17-25 09:35AM
09:23AM
09:16AM
06:20AM
Jun-16-25 05:07PM
04:19PM
04:13PM
04:05PM Loading…
04:05PM
03:51PM
03:15PM
02:31PM
01:37PM
12:30PM
12:19PM
11:59AM
11:10AM
10:24AM
09:12AM
08:45AM
08:00AM
07:55AM
06:18AM
05:18AM Loading…
05:18AM
05:17AM
Jun-15-25 01:00AM
Jun-10-25 12:31PM
12:38AM
Jun-07-25 09:40AM
Jun-05-25 05:39PM
11:31AM
10:03AM
Jun-04-25 01:00PM
09:30AM
May-27-25 10:03AM
May-22-25 06:52AM
May-21-25 08:30AM
May-19-25 10:04AM
07:36AM
May-16-25 09:01AM
09:00AM
May-14-25 08:30AM
May-13-25 09:25AM
04:14AM
May-11-25 04:41PM
May-09-25 12:01PM
08:48AM
May-08-25 04:30PM
10:36AM
05:01AM
May-07-25 04:17PM
02:14PM
01:32PM
12:14PM
11:25AM
09:41AM
08:31AM
07:46AM
07:46AM
07:29AM
03:19AM
May-06-25 10:41PM
06:00PM
05:35PM
04:05PM
May-05-25 08:00AM
04:44AM
May-04-25 06:46AM
May-01-25 12:36AM
Apr-30-25 10:01AM
Apr-29-25 08:24PM
10:01AM
Apr-24-25 07:54AM
Apr-22-25 08:30AM
Apr-21-25 10:19PM
04:09PM
Apr-16-25 07:32AM
Apr-15-25 08:30AM
Apr-11-25 02:13PM
Apr-10-25 05:00AM
Apr-09-25 01:45PM
Apr-08-25 04:50PM
07:30AM
05:14AM
Apr-07-25 08:09AM
07:21AM
Apr-04-25 10:38AM
09:25AM
08:44AM
07:29AM
Apr-03-25 04:27PM
03:37PM
03:23PM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barry RichardDirectorMay 16 '25Option Exercise32.6312,350402,9812,966,667May 19 07:32 AM
Barry RichardDirectorMay 13 '25Option Exercise19.2320,246389,3592,954,317May 15 07:00 AM
Nicaise ClaudeDirectorMar 12 '25Option Exercise25.189,746245,40430,303Mar 13 08:00 PM
Nicaise ClaudeDirectorMar 12 '25Sale99.642,491248,20327,812Mar 13 08:00 PM
Nicaise ClaudeDirectorMar 12 '25Proposed Sale99.652,491248,226Mar 12 05:33 PM
Estepan Ian MichaelChief Financial OfficerJan 29 '25Option Exercise12.0015,800189,60049,496Jan 31 08:30 PM
Wigzell Hans Lennart RudolfDirectorDec 12 '24Option Exercise13.7110,500143,95533,340Dec 16 08:00 PM
Wigzell Hans Lennart RudolfDirectorDec 12 '24Sale124.8410,5001,310,82022,840Dec 16 08:00 PM
Wigzell Hans Lennart RudolfDirectorDec 12 '24Proposed Sale124.8010,5001,310,400Dec 12 05:06 PM
Boor Kathryn JeanDirectorDec 05 '24Sale125.551,636205,4005,880Dec 06 08:00 PM
Boor Kathryn JeanDirectorDec 05 '24Proposed Sale125.551,636205,400Dec 05 04:18 PM
Estepan Ian MichaelChief Financial OfficerAug 30 '24Sale137.365,985822,10033,946Sep 03 08:00 PM
Estepan Ian MichaelOfficerAug 30 '24Proposed Sale137.375,985822,130Aug 30 05:03 PM
Chambers Michael AndrewDirectorAug 16 '24Buy133.8037,0384,955,728284,034Aug 20 08:00 AM
BEHRENS M KATHLEENDirectorJul 03 '24Option Exercise13.9015,000208,500191,839Jul 08 08:00 PM
Brown Ryan EdwardEVP, General CounselJun 25 '24Option Exercise62.7723,5001,475,09556,086Jun 25 08:00 PM
Brown Ryan EdwardEVP, General CounselJun 25 '24Sale161.6138,9576,296,02917,129Jun 25 08:00 PM
Arif BilalChief Tech Ops OfficerJun 24 '24Sale163.087,8591,281,62121,261Jun 25 08:00 PM
Arif BilalChief Tech Ops OfficerJun 25 '24Sale163.233,898636,27117,363Jun 25 08:00 PM